Work

A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.tps538

Authors: Guru Sonpavde, Solange Peters, Luke T. Nordquist, Terufumi Kato, Paulo Andre Miranda, Qin Wang, Mark A. Socinski

Institutions: Dana-Farber Cancer Institute, Centre Hospitalier Universitaire Vaudois, Urology Cancer Center and GU Research Network, Kanagawa Cancer Center, AstraZeneca (United Kingdom), Florida Hospital Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2793511528

Cites:

Cited by: 2

Related to: 10